ArticleFrontiers in neurology
Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: There is limited data regarding the use of antiseizure medications (ASMs) for autoimmune encephalitis (AE)-related seizures and epilepsy, particularly in pediatric patients. Perampanel (PER) was associated with seizure improvement in controlling seizures of inflammatory etiology. The objective of this study was to describe seizure outcomes and tolerability after PER administration in pediatric patients with AE-related seizures and epilepsy. Methods: This retrospective, single-center study (2020-2025) reviewed 14 pediatric patients diagnosed with AE who received PER during either the acute symptomatic phase or the chronic phase of autoimmune-associated epilepsy. Clinical data, seizure outcomes, concomitant treatments, and adverse events were retrospectively collected and descriptively analyzed. Results: Fourteen pediatric patients with AE (9 male, 5 female; median age 8.5 years) were treated with PER. The median maintenance dose of PER ranged from 2 to 4 mg per day. According to the classification by the International League Against Epilepsy (ILAE), the patients were divided into two groups: (a) acute symptomatic seizures secondary to AE (ASSAE), and (b) autoimmune-associated epilepsy (AAE). In the ASSAE group, 42.8% (3/7) of the patients achieved seizure resolution during the acute phase. In the AAE group, at the 3-month endpoint, 57.1% (4/7) of patients achieved a ≥ 50% reduction in seizure frequency compared to baseline, meeting the responder criteria. Additionally, 42.8% (3/7) of patients in the AAE group achieved seizure freedom at the 3-month endpoint. No serious adverse events were reported in either group. Conclusion: In this small retrospective case series, seizure improvement was observed in some pediatric patients with AE-related seizures or epilepsy after PER administration, without serious adverse events. Because most patients received concomitant ASMs and immunotherapy, these findings should be interpreted as preliminary and hypothesis-generating. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=191349, identifier: ChiCTR2300074696.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.